Literature DB >> 21961513

Developing an algorithm to convert routine measures of vision into utility values for glaucoma.

Yasmene Alavi1, Mireia Jofre-Bonet, Catey Bunce, Richard P Wormald, Ananth Viswanathan, Allen Foster, Roger Hitchings.   

Abstract

PURPOSE: Measures of quality of life called utility values (UVs) are needed to deliver the most cost-effective health care for glaucoma patients. UVs are rarely measured in clinical research and practice whereas clinical outcomes such as visual field are routinely collected. The aim of this study was to develop an algorithm that calculates UVs directly from combinations of routine measures of binocular visual field, visual acuity, and contrast sensitivity.
METHODS: A total of 132 outpatients with primary open angle glaucoma were recruited. The Time Trade-off (TTO) question was administered during face-to-face interviews. Binocular ETDRS logMAR visual acuity (VA(B)), binocular Pelli-Robson contrast sensitivity (CS(B)), and Humphrey 24-2 monocular visual field tests were performed on the same day. Integrated (binocular) visual field (IVF) scores were derived. Tobit regression analyses were used to model utility values based on combinations of IVF, VA(B), CS(B) and other controlling factors.
RESULTS: UVs recorded for 123 cases correlated significantly with both clinical measures of binocular visual function (r = -0.47, IVF; r = -0.48, VA(B); r = 0.50, CS(B); P <0.0001) and measures of vision-specific quality of life (r = 0.54-0.6, P <0.0001). Two final models incorporate terms for IVF and VA(B), with or without living arrangements, and explain 22% and 31% of variation in utilities. CS(B) was not included in either model due to co-linearity between CS(B) and VA(B) confounding the models.
CONCLUSION: The models provide preliminary algorithms for predicting the expected UVs for glaucoma populations directly from clinical outcomes collected routinely in clinical practice.

Entities:  

Mesh:

Year:  2011        PMID: 21961513     DOI: 10.3109/09286586.2011.602577

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  8 in total

1.  Time Trade-off Utility Values in Noninfectious Uveitis.

Authors:  Katherine M Niemeyer; John A Gonzales; Thuy Doan; Erica N Browne; Maya M Rao; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2019-06-13       Impact factor: 5.258

2.  Estimating quality-adjusted life years from patient-reported visual functioning.

Authors:  C Browne; J Brazier; J Carlton; Y Alavi; M Jofre-Bonet
Journal:  Eye (Lond)       Date:  2012-07-06       Impact factor: 3.775

3.  [Conventional perimetry. Antiquated or indispensable for functional glaucoma diagnostics?].

Authors:  F Tonagel; B Voykov; U Schiefer
Journal:  Ophthalmologe       Date:  2012-04       Impact factor: 1.059

4.  Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality.

Authors:  Thomas Butt; Michael D Crossland; Peter West; Shepley W Orr; Gary S Rubin
Journal:  Br J Ophthalmol       Date:  2014-10-28       Impact factor: 4.638

5.  Preference-based disease-specific health-related quality of life instrument for glaucoma: a mixed methods study protocol.

Authors:  Sergei Muratov; Dominik W Podbielski; Susan M Jack; Iqbal Ike K Ahmed; Levine A H Mitchell; Monika Baltaziak; Feng Xie
Journal:  BMJ Open       Date:  2016-11-08       Impact factor: 2.692

6.  Quality of Life of Patients with Glaucoma in Slovakia.

Authors:  Ľudmila Majerníková; Anna Hudáková; Andrea Obročníková; Beáta Grešš Halász; Mária Kaščáková
Journal:  Int J Environ Res Public Health       Date:  2021-01-09       Impact factor: 3.390

7.  A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma.

Authors:  Fiammetta Maria Bozzani; Yasmene Alavi; Mireia Jofre-Bonet; Hannah Kuper
Journal:  BMC Ophthalmol       Date:  2012-08-21       Impact factor: 2.209

8.  Visual function evaluation for low vision patients with advanced glaucoma.

Authors:  Soo Ji Jeon; Younhea Jung; Chang-Sub Jung; Hae-Young Lopilly Park; Chan Kee Park
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.